2-methyl-5-nitropyridin-3-amine (Cas 51984-61-3)

We are instrumental in manufacturing exporting trading and supplying 2-Methyl-5-Nitropyridin-3-Amine (CAS 51984-61-3) in Minhang Shanghai China is an intermediate for Flumatinib an antineoplastic tyrosine kinase inhibitor used for the treatment of chronic myelogenous leukemia (CML).

Currently in China Flumatinib is at Phase I clinical trials for the treatment of chronic myelogenous leukemia (CML).
CML is a chronic myeloproliferative disease characterized by an overproduction of immature myeloid cells and mature granulocytes. CML is developed by the Philadelphia chromosome a reciprocal chromosome translocation t(9;22) which causes a constitutive activation of the BCR-ABL tyrosine kinase (Deininger et al. 2000; Ren 2005). As a result current CML treatment strategies involve the use of tyrosine kinase inhibitors such as imatinib (Chemical name 4-(4-methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide) nilotinib and dasatinib (Sawyers 2001; Kantarjian et al. 2006; Steinberg 2007).
Flumatinib is like imatinib in structure but nonclinical studies have shown that Flumatinib was predominantly metabolized by amide bond cleavage to yield two corresponding hydrolytic products. By comparison with imatinib the electron-withdrawing groups of trifluoromethyl and pyridine facilitated the amide bond cleavage and led to the in vivo formation of a carboxylic acid and an amine.